Provectus Biopharmaceuticals
PVCT
PVCT was delisted on the 13th of October, 2016.
3 hedge funds and large institutions have $5K invested in Provectus Biopharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, reducing their positions, and 4 closing their positions.
62% less capital inflows, than outflows
Capital inflows: $758 | Capital outflows: $2K
63% less funds holding
Funds holding: 8 → 3 (-5)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Focused Wealth Management
Newburgh,
New York
|
+$758 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cutter & Co Brokerage
Ballwin,
Missouri
|
-$2K |
PVCT Hedge Fund Activity: Q1 2017 in Review
3 of the 4,036 institutional investors tracked by Wall St. Rank reported a position in Provectus Biopharmaceuticals (PVCT) for Q1 2017, worth a combined $5K — up 25% from $4K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of PVCT and 0 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was Focused Wealth Management, adding an estimated $758. The largest seller was Cutter & Co Brokerage, exiting entirely with an estimated $2K sold.
- 3 institutional investors held Provectus Biopharmaceuticals (PVCT) as of Q1 2017, down from 8 in Q4 2016.
- Funds reported $5K of Provectus Biopharmaceuticals stock for Q1 2017, up 25% quarter-over-quarter.
- 0 funds opened new Provectus Biopharmaceuticals positions in Q1 2017 and 4 closed out, a net change of -4 holders.
- The largest Provectus Biopharmaceuticals buyer in Q1 2017 was Focused Wealth Management, an estimated $758 added.
- The largest Provectus Biopharmaceuticals seller in Q1 2017 was Cutter & Co Brokerage, an estimated $2K sold.
Based on aggregated 13F filings for Q1 2017.